1 Sep 2015 07:04
For Immediate Release 1 September 2015
Sphere Medical Holding plc
("Sphere Medical" or the "Company")
Notice of Interim Results
Sphere Medical Holding plc (AIM: SPHR.L), a leading provider of innovative monitoring and diagnostic devices for the critical care setting, will announce its interim results for the six months ended 30 June 2015 on Tuesday 22 September 2015.
Dr. Wolfgang Rencken, Chief Executive Officer and Richard Wright, Chief Financial Officer, will host a presentation and conference call at 10:00 am on the day of the results at finnCap's offices, 60 New Broad Street, London, EC2M 1JJ.
Conference call ID: 24893679
UK: +44 1452 555 566
- Ends -
For further information, please contact:
Sphere Medical Holding plc | Tel: +44 (0)1223 875 222 | |
Dr Wolfgang Rencken, Chief Executive Officer | ||
Richard Wright, Chief Financial Officer | ||
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 | |
James Steel | ||
Oliver Jackson | ||
Jock Maxwell Macdonald | ||
finnCap | Tel: +44 (0) 20 7220 0500 | |
Geoff Nash / Simon Hicks | ||
Stephen Norcross | ||
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 | |
Mary-Jane Elliott | spheremedical@consilium-comms.com | |
Chris Gardner Ivar Milligan | ||
Hendrik Thys | ||
Notes for Editors
About Sphere Medical (AIM: SPHR.L)
Sphere Medical is a medical device company developing and commercialising a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.
Sphere Medical's vision is to become a leading solution provider to the critical care market offering innovative, near real time, point of care diagnostic and monitoring products to enable closer control of therapeutic response and improve patient outcomes and reduce the overall cost of care.
The Company's strategy is focused on developing the Proxima (CE marked device) platform for measuring blood gases, electrolytes and metabolites. The Company is already marketing its Proxima product directly to the critical care market, which includes the ICU and OR, with a dedicated field sales force in the UK, Germany, the Netherlands and Belgium. The Company also proposes to work with partners for the worldwide distribution of Proxima.
Proxima delivers near real time analysis of blood gases and electrolytes metabolites, at the patient's bedside. Proxima can be used on patients across a wide therapeutic range, enabling faster clinical decision making and improved patient outcomes, whilst potentially reducing costs for healthcare payers.
For further information, please visit www.spheremedical.com
Sphere Medical Holding (SPHR)